克隆技术/蛋白质转染试剂/100 Rxns/631324

价格
¥5780.00
货号:631324
浏览量:127
品牌:Clontech
服务
全国联保
正品保证
正规发票
签订合同
商品描述

Protein transfection reagents

The Xfect Protein Transfection Reagent uses a cell-penetrating peptide to bind and transport active proteins directly into a wide variety of mammalian cell types, including hard-to-transfect human suspension cell lines and mouse embryonic stem cells.

The Xfect Protein Transfection Reagent uses a cell-penetrating peptide to bind and transport active proteins directly into a wide variety of mammalian cell types, including hard-to-transfect human suspension cell lines and mouse embryonic stem cells.

What is the Xfect Protein Transfection Reagent and how does it work?

Xfect Protein Transfection Reagent is a modified peptide with cell-penetrating activity whose amino acid composition enables it to interact with a protein cargo and transport this protein across a cell membrane barrier. Just incubate your protein of interest with the Xfect reagent in the supplied buffer for 30 minutes and then apply the mixture to your cells. Two hours later you are ready to assay for protein activity.

Why transfect purified proteins directly?

Protein transfection is extremely rapid compared to traditional gene expression studies using transfected DNA (1–2 hours compared to 18–48 hours) because it bypasses cellular processes such as transcription and translation. It also facilitates studies involving transient effects of proteins, and avoids potentially harmful random DNA integration into the genome of the target cells. Xfect Protein Transfection Reagent makes it possible to deliver active proteins directly into cells for studies that involve transcriptional regulation, the cell cycle, apoptosis, oncogenesis, epigenetics, cell regeneration, and transdifferentiation.

What are the advantages of Xfect Transfection Reagent compared to other protein delivery technologies?

The two technologies most frequently used for protein delivery are based on lipids and cell-penetrating peptides. Lipid-based reagents tend to demonstrate high cytotoxicity, while peptide-based reagents transfect with low efficiency. Xfect Protein Transfection Reagent offers the best advantages of both, i.e., it retains low cytotoxicity and delivers more protein to a higher percentage of target cells (see Image Data tab in the product details section below). Moreover, Xfect Protein Transfection Reagent can transfect cells that are growing at a higher density than competing products, which is important since assays are often performed within a few hours post-transfection and the higher cell densities ensure sufficient material for downstream analysis.

 More Less
美国Clontech www.clontech.com www.takara.com.cn www.takara-bio.com www.takara.co.jp 2005年7月1日,日本最大的生物工程公司TaKaRa公司据说花费了6千万美元成功此收购计划已经于2005年8月底完成,Clontech已成为TaKaRa全资子公司。美国Clontech是1984年由华人方瑞贤创立的,一度曾经是众多海外华人的骄傲。因为方瑞贤创立的是全美第一家,也是建立了最大的分子生物公司,更重要的是Clontech建立了生物技术中建立基因文库的模式。在Clontech被BD收购时已有四百名员工,包括六十五位博士,拥有五十多个专利,产品已达两千多个,堪称全球数一,数二的基因库,提供全球三十多个国家基因实验室或学术界做研究之用。该公司有曾于预期四,预期五,预期八及预期九年被圣荷西及旧金山商业报纸选为一百个成长速度的私人公司。Clontech公司一直锐意进取,其开发的产品多次获得全美R&D100金奖。产品范围包括基因识别,基因表达,基因功能研究,大家熟悉的Smart Race,Altas DNA矩阵,SSH消减杂交,MTN膜,多色荧光蛋白载体,MatchMaker酵母双杂交系列也在其中。TaKaRa公司于1979年年从生产限制性内切酶起步,首先将PCR技术引入日本市场,并逐渐成为日本生命科学研究领域领先的公司.TaKaRa在2004年财政年度试剂销售达到118亿日元(1十亿美元左右),其中85%的收益来自于日本本土市场,其他有部分来自于中国等亚洲市场。此次收购会给Takara带来以下收益:极大地丰富Takara原来的产品线;迅速扩大TaKaRa在欧美市场的份额,因为Clontech 70%以上的销售是来自于欧美,而Takara 85%的收益来自于日本本土市场。本次收购将全面扩展日本产品在欧美的销售。另外宝将整合并加强日本本土和位于美国的Clontech公司研发部,加快产品的开发,提高宝在全球生命科学研究市场的份额。